Powered by

Foghorn® Therapeutics Announces Collaboration with Merck to Discover and Develop Novel Oncology Therapeutics Against Transcription Factor Target

Jul 08, 2020 - Business Wire
Partnership Announcement

Foghorn® Therapeutics Inc., a company advancing an unprecedented class of therapeutics targeting the chromatin regulatory system in oncology, announced that it has entered into a strategic collaboration with Merck, known as MSD outside the United States and Canada. The collaboration will apply Foghorn's proprietary Gene Traffic Control(TM) product platform to discover and develop novel therapeutics against a transcription factor target believed to be relevant to a broad range of cancer patients...